The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1311
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Fenofibric Acid (Trilipix)

The FDA has approved the marketing of fenofibric acid (Trilipix – Abbott) to reduce triglycerides and increase HDL-C in patients with mixed dyslipidemia on optimal doses of a HMG-CoA reductase inhibitor (statin) who have, or have risk factors for, coronary heart disease. It is the first fibrate approved by the FDA specifically for combined use with a statin. Trilipix is also approved as monotherapy for hypertriglyceridemia, hypercholesterolemia and low HDL-C. The patent for Tricor, Abbott’s older formulation of fenofibrate, will expire in 2011.

FENOFIBRATES — Fenofibrate is available in nonmicronized tablets and capsules that are poorly absorbed and usually must be taken with a meal, and in micronized capsules that are more reliably absorbed. Fenofibric acid is the active metabolite of fenofibrate. Trilipix is the active choline salt of fenofibric acid; it is available as a delayed-release ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1311
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian